Artikel
Treatment of interleukin 6 inhibitor in severe ankylosing spondylitis with second AA-amyloidosis
Suche in Medline nach
Autoren
Veröffentlicht: | 14. September 2021 |
---|
Gliederung
Text
Introduction: Inhibitors of interleukin 6 (IL6) have been found to be ineffective in ankylosing spondylitis (AS) based on the results of randomized clinical trials (RCTs) on tocilizumab (TCZ) and sarilimumab. However, there is evidence that IL6 is actively involved in the pathogenesis of the disease. In addition, the efficacy of IL6 inhibitors has been shown in patients with secondary AA-amyloidosis. Aim: to analyze the effectiveness of IL6 inhibitor - TCZ in patients with AS with high disease activity and secondary AA-amyloidosis.
Methods: The analysis included 10 patients with AS receiving TCZ therapy, of which 8 (80%) men, 2 (20%) women, and 100% HLA B27 positive. The average age of the patients was 40 ± 8.6 years, the average duration of AS was 25.6 ± 6.5 years. 9 patients had histologically confirmed secondary AA-amyloidosis: 100% had kidney amyloidosis, 6 (66.6%) patients also had gastrointestinal amyloidosis and 3 (33.4%) patients had heart amyloidosis. The average duration of TCZ treatment was 22.0 months [1.0; 36.0]. 8 (80%) patients continue to take TCZ therapy to date, and 2 (20%) - are transferred to TNF-α inhibitors.
Results: Table 1 [Tab. 1] shows the main clinical and laboratory characteristics of patients at the initiation of TCZ therapy and during the therapy. As you can see, against the background of TCZ therapy, both the level of CRP, proteinuria and the indices of AS activity (BASDAI, ASDAS CRP) significantly decreased. The number of patients with inflammatory back pain (IBP), arthritis and coxitis also decreased significantly.
Conclusion: The above data showed that the method of treating AS with IL6 inhibitors, in certain clinical situations, primarily such as ineffectiveness of TNF-α inhibitors, high CRP level and the development of secondary AA-amyloidosis, can be highly effective.
Disclosures: no.